Atormac
Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 857  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 »   Next article
 »   Previous article
 »   Table of Contents

 Resource Links
 »   Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »   Citation Manager
 »   Access Statistics
 »   Reader Comments
 »   Email Alert *
 »   Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed141    
    Printed5    
    Emailed0    
    PDF Downloaded8    
    Comments [Add]    

Recommend this journal

 

 CASE REPORT
Year : 2020  |  Volume : 68  |  Issue : 2  |  Page : 478--480

A Case of High Grade Glioma Following Treatment of Relapsing-Remitting Multiple Sclerosis with Fingolimod


1 Department of Radiology, Inonu University, Malatya, Turkey
2 Department of Neurology, School of Medicine, Inonu University, Malatya, Turkey

Correspondence Address:
Ozden Kamisli
Department of Neurology, School of Medicine, Inonu University, Malatya
Turkey
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0028-3886.284361

Rights and Permissions

Multiple sclerosis is a major cause of neurological disability, especially in young adults. There have been several case reports of an increased risk of cancer after long-term treatment for multiple sclerosis. Fingolimod is an immunomodulating agent used in the treatment of relapsing-remitting multiple sclerosis. The side effects commonly associated with fingolimod are cardiac side effects, macular edema, and elevated liver enzyme levels. Increased risks of infection and cancer have also been reported. High grade glioma is an aggressive primary brain tumor. There has been one case report of high grade glioma during fingolimod treatment. Here, we report the case of a 58-year-old woman diagnosed with glioblastoma multiforme after one year of fingolimod treatment for multiple sclerosis.






[FULL TEXT] [PDF]*


        
Print this article     Email this article

Online since 20th March '04
Published by Wolters Kluwer - Medknow